Each lot of this antibody is quality control tested by ELISA assay. For ELISA or ELISPOT detection, the antibody should be titrated between 0.25-1.0 ?g/ml to determine optimal conditions. To obtain a linear standard curve, serial dilutions of IL-10 recombinant protein ranging from 2000 to 15 pg/ml are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.

ELISA or ELISPOT Detection^1,9,11: The biotinylated JES5-16E3 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified JES5-2A5 antibody (Cat. Nos. 504902 & 504904) as the capture antibody.
ELISA Capture: The purified JES5-16E3 antibody is useful as the capture antibody in a sandwich ELISA when used in conjunction with the biotinylated JES5-2A5 antibody (Cat. No. 505003) as the detection antibody and recombinant mouse IL-10 (Cat. No. 575809) as the standard.
Neutralization¹⁴: The Ultra-LEAF? purified JES5-16E3 antibody can neutralize the bioactivity of natural or recombinant IL-10.
Flow Cytometry³: The fluorochrome-labeled JES5-16E3 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IL-10-producing cells within mixed cell populations.
Additional reported applications (for relevant formats) include: immunohistochemistry³.

1. Simkin G, et al. 2000. J. Immunol. 164:2457.
2. Kitagaki K, et al. 2002. Clin. Diagn. Lab Immunol. 9:1260.
3. Khanna A, et al. 2000. J. Immunol. 164:1346.
4. Sander B, et al. 1993. J. Immunol. Methods 166:201.
5. Litton M, et al. 1994. J. Immunol. Methods 175:47.
6. Andersson U, et al. 1999. Detection and qunatification of gene expression. New York:Springer-Verlag.
7. Finkelman F, et al. 2003. Curr. Prot. Immunol. John Wiley & Sons New York. Unit 6.28.
8. Wang W, et al. 2004. FASEB J. 18:1043.
9. Brummel R and Lenert P. 2005. J. Immunol. 174:2429.
10. Lawson BR, et al. 2007. J. Immunol. 178:5366.
11. Xu G, et al. 2007. J. Immunol. 179:5358. PubMed
12. Brummel R, et al. 2005. J. Immunol.174:2429. PubMed
13. Kang YJ, et al. 2007. Stem Cells 25:1814. PubMed
14. Seo N, et al. 2001. Immunology. 103:449. (Neut)

1. Godebu E, et al. 2008. J Immunol. 181:1798. PubMed
2. Cox N, et al. 2015. Proc Natl Acad Sci U S A. 112: 8385 - 8390. PubMed
3. Campos–Mora M, et al. 2019. Front Immunol. 1.029166667. PubMed
4. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. de Waal-Malefy R, et al. 1992. Curr. Opin. Immunol. 4:314.
3. Howard M, et al. 1992. Immunol. Today 13:198.
4. Quesniaux V. 1992. Res. Immunol. 143:385.
5. Norton SK, et al. 2008. J. Immunol. 180:2848.